1. Rein Therapeutics' abstract accepted at ATS 2025 International Conference. 2. Presentation focuses on alveolar regenerative properties in lung samples. 3. LTI-03 Phase 2 trial for idiopathic pulmonary fibrosis expected soon. 4. LTI-01 has Orphan Drug and Fast Track Designation in the U.S. 5. Company aims to address unmet needs in pulmonary and fibrosis indications.
The acceptance of the abstract demonstrates academic interest, potentially attracting investors. Historically, positive news related to research presentations boosted similar biopharma stocks.
The article highlights a significant research milestone for RNTX, likely affecting its stock price due to increased visibility.
Anticipated Phase 2 trial initiation will attract near-term investor interest. Previous successful trials in similar domains typically yield rapid market reactions.
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that an abstract has been accepted at the American Thoracic Society (ATS) 2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.
Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres from IPF and Normal Donor Lung Samples
Poster #: P1463
Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis
Date & Time: Monday, May 19, 2025, at 11:30 AM PT / 2:30 PM ET
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.
For more information, please visit the company's website at reintx.com, or follow them on LinkedIn and X.
Argot Partners
[email protected] 212-600-1902
SOURCE Rein Therapeutics, Inc.